Inhibitors of topoisomerase II as pH-dependent modulators of etoposide- mediated cytotoxicity

Clinical Cancer Research

Volumn 5, Issue 10, 1999, Pages 2899-2907

  Langer, Seppo W ^a,b   Schmidt, Günther ^a,b   Sørensen, Morten ^a,b   Sehested, Maxwell ^b   Jensen, Peter Buhl ^a  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOACRIDINE; AMODIAQUINE; CHLOROQUINE; ETOPOSIDE; HYDROXYCHLOROQUINE; MEPACRINE; QUININE;

ARTICLE; CELL LEVEL; CELL PH; CELL PROTECTION; DRUG DNA BINDING; DRUG EFFECT; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; HYDROGEN-ION CONCENTRATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032718228     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bork, E., Ersbøll, J., Dombernowsky, P., Bergman, B., Hansen, M., and Hansen, H. H. Teniposide and etoposide in previously untreated small cell lung cancer: a randomized study. J. Clin. Oncol., 9; 1627-1631, 1991.
2. Vaupel, P., Kallinowski, F., and Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res., 49: 6449-6465, 1989.
3. Newell, K., Franchi, A., Pouyssegur, J., and Tannock, I. F. Studies with glycolysis-deficient cells suggest that production of lactic acid is not the only cause of tumor acidity. Proc. Natl. Acad. Sci. USA, 90: 1127-1131, 1993.
4. Boyer, M. J., and Tannock, I. F. Regulation of intracellular pH in tumor cell lines: influence of microenvironmental conditions. Cancer Res., 52: 4441-4447, 1992.
5. Holm, B., Sehested, M., and Jensen, P. B. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide. Clin. Cancer Res., 4: 1367-1373, 1998.
6. Jensen, P. B., Sørensen, B. S., Demant, E. J. F., Sehested, M., Jensen, P. S., Vindeløv, L., and Hansen, H. H. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res, 50: 3311-3316, 1990.
7. Jensen, P. B., Sørensen, B. S., Sehested, M., Grue, P., Demant, E. J. F., and Hansen, H. H. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res., 54: 2959-2964, 1994.
8. Sehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E., and Demant, E. J. F. Antagonistic effect of the cardioprotcctor (+)-1,2,-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46: 389-393, 1993.
9. Andoh, T., and Ishida, R. Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta, 1400: 155-171, 1998.
10. Sorensen, M., Sehested, M., and Jensen, P. B. pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine. Biochem. Pharmacol., 54: 373-380, 1997.
11. Holm, B., Jensen, P. B., Sehested, M., and Hansen, H. H. In vivo inhibition of etoposide-mediated apoptosis, toxicity and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother. Pharmacol., 34: 503-508, 1994.
12. de-Leij, L., Postmus, P. E., Buys, C. H., Elema, J. D., Ramaekers, F., Poppema, S., Brouwer, M., van der Veen, V., Mesander, G., and The, T. H. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res., 45: 6024-6033, 1985.
13. Carney, D. N., Gazdar, A. F., Bepler, G., Guccion, J. G., Marangos, P. J., Moody, T. W., Zweig, M. H., and Minna, J. D. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res., 45: 2913-2923, 1985.
14. Roed, H., Christensen, I. J., Vindeløv, L. L., Spang-Thomsen, M., and Hansen, H. H. Interexperiment variation and dependence on culture conditions in assaying the chemosensitivity of human small cell lung cancer cell lines. Biochem. Pharmacol., 54: 373-380, 1997.
15. Skovsgaard, T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res., 38: 1785-1790, 1978.
16. Sahai, B. M., and Kaplan, J. G. A quantitative decatenation assay for type II topoisomerases. Anal. Biochem., 156: 364-379, 1986.
17. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51: 879-886, 1996.
18. Sørensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B., and Westergaard, O. Mode of action of topoisomerase II targeting agents at a specific DNA sequence: uncoupling the DNA binding, cleavage and religation events. J. Mol. Biol., 228: 778-786, 1992.
19. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. Structure and mechanism of DNA topoisomerase II. Nature (Lond.), 379: 225-232, 1996.
20. Roca, J., Ishida, R., Berger, J. M., Andoh, T., and Wang, J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA, 91: 1781-1785, 1994.
21. Roca, J., and Wang, J. C. DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism. Cell, 77: 609-616, 1994.
22. Tanabe, K., Ikegami, Y., Ishida, R., and Andoh, T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res., 51: 4903-4908, 1991.